Coronary Leukotriene Levels and Myocardial Ischemia

  • Robert E. Goldstein
  • Giora Feuerstein
  • David Ezra
  • Gordon Letts
  • Peter W. Ram-Well
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


Potential for Involvement of Cysteinyl Leukotrienes in Myocardial Infarction Several lines of evidence suggest that leukotrienes might be involved in the path-ogenesis of myocardial infarction. Cysteinyl leukotrienes released by inflammatory cells have a potent capacity to cause vasoconstriction and edema formation. Administration of cysteinyl leukotrienes to blood-perfused, in situ hearts can produce profound coronary constriction accompanied by electrocardiographic evidence of myocardial ischemia, depression of myocardial contractility, and ventricular arrhythmias (Michelassi et al., 1982; Woodman and Dusting, 1983; Ezra et al., 1983). Figure 1 illustrates the influence of leukotriene C4 as observed in our laboratory. In this example, a l-μg bolus of leukotriene C4, given directly into the left anterior descending coronary artery of a pig, caused transient arrest of regional blood flow and ST segment elevation characteristic of myocardial ischemia on a local surface electrocardiogram. Left ventricular end-diatolic pressure is not altered in this example. In other experiments, however, regional wall motion, recorded by epicardial sonomicrometers in myocardium supplied by the left anterior descending coronary artery, demonstrated transient, severe reduction in myocardial shortening in conjunction with marked leukotriene-induced coronary flow decrement (Mich-elassi et al., 1982; Ezra et al., 1984). Thus, release of cysteinyl leukotrienes within the heart might have substantial deleterious consequences for coronary and myocardial function.


Myocardial Ischemia Left Anterior Descend Coronary Flow Coronary Blood Flow Coronary Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Capurro, N., and Levi, R., 1975, The heart as target organ in systemic allergic reactions: Comparison of cardiac anaphylaxis in vivoand in vitro, Circ. Res. 36:520–528.CrossRefGoogle Scholar
  2. Coker, S.J., Parratt, J.R., McAledingham, I., and Zeitlin, I.J., 1981, Early release of thromboxane and 6-keto-PGF from the ischaemic canine myocardium; relation to early post-infarction arrhythmias, Nature 291:323–324.PubMedCrossRefGoogle Scholar
  3. Del Maestro, R., Thaw, H., Bjork, J., Planker, M., and Arfors, K., 1980, Free radicals as mediators of tissue injury, Acta Physiol. Scand. [Suppl.J 492:43–47.Google Scholar
  4. Engler, R. L., Dahlgren, M., Schmidt-Schoenbein, G., Witztum, K., Dobbs, A., and Peterson, M., 1984, Early accumulation of granulocytes in ischemic myocardium, Clin. Res. 32:162A.Google Scholar
  5. Ezra, D., Boyd, L.M., Feuerstein, G., and Goldstein, R.E., 1983, Coronary constriction by leukotriene C4, D4, and E4 in the intact pig heart, Am. J. Cardiol. 51:1451–1454.PubMedCrossRefGoogle Scholar
  6. Ezra, D., Feuerstein, G., Erne, J., and Goldstein, R.E., 1984, Biphasic coronary flow response to sustained leukotriene D4 administration, J. Am. Coll. Cardiol. 3:502.Google Scholar
  7. Fantone, J.C., and Ward, P.A., 1982, Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions, Am. J. Pathol. 107:397–418.Google Scholar
  8. Feuerstein, G., Boyd, L. M., Ezra, D., and Goldstein, R. E., 1984, Effect of platelet-activating factor on coronary circulation of the domestic pig, Am. J. Physiol. 246 (Heart Circ. Physiol. 15):H466–H471.PubMedGoogle Scholar
  9. Fiedler, V.B., 1983a, Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat, Eur. J. Pharmacol. 88:263–267.PubMedCrossRefGoogle Scholar
  10. Fiedler, V.B., 1983b, The effects of oral nafaztrom ( = Bay g6575) on canine artery thrombosis and myocardial ischemia, Basic Res. Cardiol. 78:266–280.PubMedCrossRefGoogle Scholar
  11. Fujiwara, H., Ashraf, M., Sato, S., and Millard, R.W., 1982, Transmural cellular damage and blood flow distribution in early ischemia in pig hearts, Circ. Res. 51:683–693.PubMedCrossRefGoogle Scholar
  12. Granstrom, E., and Kindahl, H., 1976, Radioimmunoassay for prostaglandin metabolites, Adv. Pros-taglandin Thromboxane Res. 1:81–92.Google Scholar
  13. Hayes, E.C, Lombardo, D.L., Girard, Y., Maycock, A.L., Rokach, J., Rosenthal, A.S., Young, R.N., Egan, R.W., and Zweerink, H.J., 1983, Measuring leukotrienes of slow reacting subtances of anaphylaxis: Development of a specific radioimmunoassay, J. Immunol. 131:429–433.PubMedGoogle Scholar
  14. Kloner, R.A., Ganote, C.E., and Jennings, R.B., 1974, The “no-flow” phenomenon after temporary coronary occlusion in the dog, J. Clin. Invest. 54:1496–1508.PubMedCrossRefGoogle Scholar
  15. Michelassi, F., Landra, L., Hill, R.D., Lowenstein, E., Watkins, W.D., Petkau, A.J., and Zapol, W.M., 1982, Leukotriene D4: A potent coronary artery constrictor associated with impaired ventricular contraction, Science 217:841–843.PubMedCrossRefGoogle Scholar
  16. Mullane, K., and Bednar, M., 1984, Contribution of leukocytes to ischemia-induced myocardial damage, Clin. Res. 32:475A.Google Scholar
  17. Mullane, K.M., Read, N., Salmon, J.A., and Moncada, S., 1984, Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to myocardial salvage by anti-inflammatory drugs, J. Pharmacol. Exp. Ther. 228:510–522.PubMedGoogle Scholar
  18. Reimer, K.A., Lowe, J.E., Rasmussen, M.M., and Jenning, R.B., 1977, The wavefront phenomenon of cell death. I. Myocardial infarct size vs. duration of coronary occlusion in dogs, Circulation 56:786–794.PubMedCrossRefGoogle Scholar
  19. Romson, J.L., Hook, B.G., Rigor, V.H., Schork, M.A., Swanson, D.P., and Lucchesi, B.R., 1982, The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction, Circulation 66:1002–1011.PubMedCrossRefGoogle Scholar
  20. Sakai, K., Ito, T., and Ogawa, K., 1982, Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart, J. Cardiovasc. Pharmacol. 4:129–135.PubMedCrossRefGoogle Scholar
  21. Tanabe, M., Terashita, Z.I., Fujiwara, S., Shimamoto, N., Goto, N., Nishikawa, K., and Hirata, M., 1982, Coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion in anesthetized dogs, Cardiovasc. Res. 16:99–106.PubMedCrossRefGoogle Scholar
  22. Trachte, G.J., Lefer, A.M., Aharony, D., and Smith, J.B., 1979, Potent constriction of cat coronary arteries by hydroperoxides of arachidonic acid and its blockade by anti-inflammatory agents, Pros-taglandins 18:909–914.Google Scholar
  23. Weissman, G., Smolen, J., and Korchak, H., 1980, Release of inflammatory mediators from stimulated neutrophils, N. Engl. J. Med. 303:27–31.CrossRefGoogle Scholar
  24. Woodman, O.L., and Dusting, G.J., 1983, Coronary vasoconstriction induced by leukotrienes in the anesthetized dog, Eur. J. Pharmacol. 86:125–128.CrossRefGoogle Scholar
  25. Zaveca, J.H., and Levi, R., 1977, Separation of primary and secondary cardiovascular events in systemic anaphylaxis, Circ. Res. 40:15–19.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Robert E. Goldstein
    • 1
  • Giora Feuerstein
    • 1
  • David Ezra
    • 1
  • Gordon Letts
    • 2
  • Peter W. Ram-Well
    • 3
  1. 1.Neurobiology Research Unit, Divisions of Cardiology and Clinical Pharmacology, Departments of Medicine and PharmacologyUniformed Services University of the Health SciencesBethesdaMarylandUSA
  2. 2.Merck Frosst, Inc.DorvalCanada
  3. 3.Department of Physiology and BiophysicsGeorgetown University Medical CenterUSA

Personalised recommendations